{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:47:12Z","timestamp":1780116432768,"version":"3.54.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"National Natural Science Foundation of China (CN)","award":["81472184"],"award-info":[{"award-number":["81472184"]}]},{"name":"Doctoral Fund of Ministry of Education of China","award":["2012M521588"],"award-info":[{"award-number":["2012M521588"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0582-5","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T11:27:46Z","timestamp":1504178866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1)"],"prefix":"10.1186","volume":"36","author":[{"given":"Yixue","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"issue":"2","key":"582_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"582_CR2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jcp.21799","volume":"220","author":"HH Heng","year":"2009","unstructured":"Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol. 2009;220(3):538\u201347.","journal-title":"J Cell Physiol"},{"issue":"1","key":"582_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/cam.4.1.10885","volume":"4","author":"A Broeck Van Den","year":"2010","unstructured":"Van Den Broeck A, Ozenne P, Eymin B, Gazzeri S. Lung cancer: a modified epigenome. Cell Adhes Migr. 2010;4(1):107\u201313.","journal-title":"Cell Adhes Migr"},{"issue":"1","key":"582_CR4","first-page":"249","volume":"61","author":"S Zochbauer-Muller","year":"2001","unstructured":"Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61(1):249\u201355.","journal-title":"Cancer Res"},{"issue":"20","key":"582_CR5","doi-asserted-by":"crossref","first-page":"11891","DOI":"10.1073\/pnas.95.20.11891","volume":"95","author":"SA Belinsky","year":"1998","unstructured":"Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95(20):11891\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"582_CR6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI15475","volume":"111","author":"YC Wang","year":"2003","unstructured":"Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003;111(6):887\u201395.","journal-title":"J Clin Invest"},{"issue":"12","key":"582_CR7","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1172\/JCI68642","volume":"123","author":"KW Wagner","year":"2013","unstructured":"Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1\/2 signaling. J Clin Invest. 2013;123(12):5231\u201346.","journal-title":"J Clin Invest"},{"issue":"10","key":"582_CR8","doi-asserted-by":"crossref","first-page":"21087","DOI":"10.3390\/ijms141021087","volume":"14","author":"S Sarkar","year":"2013","unstructured":"Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14(10):21087\u2013113.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"582_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2217\/epi.10.74","volume":"3","author":"KY Wong","year":"2011","unstructured":"Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3(1):83\u201392.","journal-title":"Epigenomics"},{"issue":"5","key":"582_CR10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ijc.28563","volume":"135","author":"JW Yan","year":"2014","unstructured":"Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. Int J Cancer. 2014;135(5):1011\u20138.","journal-title":"Int J Cancer"},{"issue":"3","key":"582_CR11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1172\/JCI61271","volume":"123","author":"S Xi","year":"2013","unstructured":"Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest. 2013;123(3):1241\u201361.","journal-title":"J Clin Invest"},{"issue":"7","key":"582_CR12","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/emboj.2012.25","volume":"31","author":"K Okamoto","year":"2012","unstructured":"Okamoto K, Ishiguro T, Midorikawa Y, Ohata H, Izumiya M, Tsuchiya N, et al. miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J. 2012;31(7):1752\u201363.","journal-title":"EMBO J"},{"issue":"1","key":"582_CR13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1158\/1535-7163.MCT-11-0592","volume":"11","author":"K Ueno","year":"2012","unstructured":"Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, et al. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther. 2012;11(1):244\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"582_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/cas.12380","volume":"105","author":"H Sakai","year":"2014","unstructured":"Sakai H, Sato A, Aihara Y, Ikarashi Y, Midorikawa Y, Kracht M, et al. MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. Cancer Sci. 2014;105(4):425\u201330.","journal-title":"Cancer Sci"},{"issue":"8","key":"582_CR15","doi-asserted-by":"crossref","first-page":"e102602","DOI":"10.1371\/journal.pone.0102602","volume":"9","author":"Y Gu","year":"2014","unstructured":"Gu Y, Cheng Y, Song Y, Zhang Z, Deng M, Wang C, et al. MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One. 2014;9(8):e102602.","journal-title":"PLoS One"},{"issue":"6","key":"582_CR16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.febslet.2010.12.045","volume":"585","author":"Y Gu","year":"2011","unstructured":"Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu Y, et al. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett. 2011;585(6):881\u20137.","journal-title":"FEBS Lett"},{"issue":"12","key":"582_CR17","doi-asserted-by":"crossref","first-page":"e51413","DOI":"10.1371\/journal.pone.0051413","volume":"7","author":"B Peng","year":"2012","unstructured":"Peng B, Gu Y, Xiong Y, Zheng G, He Z. Microarray-assisted pathway analysis identifies MT1X & NFkappaB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma. PLoS One. 2012;7(12):e51413.","journal-title":"PLoS One"},{"issue":"1-2","key":"582_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11010-014-2217-x","volume":"398","author":"X Liu","year":"2015","unstructured":"Liu X, Wang C, Gu Y, Zhang Z, Zheng G, He Z. TCRP1 contributes to cisplatin resistance by preventing Pol beta degradation in lung cancer cells. Mol Cell Biochem. 2015;398(1-2):175\u201383.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"582_CR19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3892\/ol.2016.5534","volume":"13","author":"X Liu","year":"2017","unstructured":"Liu X, Feng M, Zheng G, Gu Y, Wang C, He Z. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2017;13(3):1398\u2013405.","journal-title":"Oncol Lett"},{"issue":"2","key":"582_CR20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cyto.b.20450","volume":"76","author":"PL Olive","year":"2009","unstructured":"Olive PL, Banath JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom. 2009;76(2):79\u201390.","journal-title":"Cytometry B Clin Cytom"},{"issue":"1-2","key":"582_CR21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11010-011-0880-8","volume":"357","author":"Y Gu","year":"2011","unstructured":"Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, He Z. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem. 2011;357(1-2):107\u201313.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"582_CR22","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1038\/oncsis.2017.18","volume":"6","author":"C Wang","year":"2017","unstructured":"Wang C, Liu H, Qiu Q, Zhang Z, Gu Y, He Z. TCRP1 promotes NIH\/3T3 cell transformation by over-activating PDK1 and AKT1. Oncogene. 2017;6(4):e323.","journal-title":"Oncogene"},{"issue":"4","key":"582_CR23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-015-2951-0","volume":"77","author":"JF Lv","year":"2016","unstructured":"Lv JF, Hu L, Zhuo W, Zhang CM, Zhou HH, Fan L. Epigenetic alternations and cancer chemotherapy response. Cancer Chemother Pharmacol. 2016;77(4):673\u201384.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"582_CR24","first-page":"4617","volume":"35","author":"K Harada","year":"2015","unstructured":"Harada K, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, Izumi D, et al. Suppressor microRNA-145 is epigenetically regulated by promoter Hypermethylation in esophageal Squamous cell carcinoma. Anticancer Res. 2015;35(9):4617\u201324.","journal-title":"Anticancer Res"},{"issue":"12","key":"582_CR25","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1535-7163.MCT-14-0317","volume":"13","author":"S Wang","year":"2014","unstructured":"Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther. 2014;13(12):3163\u201374.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"582_CR26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2012.04.018","volume":"342","author":"T Liloglou","year":"2014","unstructured":"Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342(2):200\u201312.","journal-title":"Cancer Lett"},{"issue":"4","key":"582_CR27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683\u201392.","journal-title":"Cell"},{"issue":"6","key":"582_CR28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1535-7163.MCT-08-0860","volume":"8","author":"L Ellis","year":"2009","unstructured":"Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8(6):1409\u201320.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"582_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-016-0537-z","volume":"15","author":"A Toll","year":"2016","unstructured":"Toll A, Salgado R, Espinet B, Diaz-Lagares A, Hernandez-Ruiz E, Andrades E, et al. MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. Mol Cancer. 2016;15(1):53.","journal-title":"Mol Cancer"},{"key":"582_CR30","doi-asserted-by":"crossref","unstructured":"Kim YH, Lee WK, Lee EB, Son JW, Kim DS, Park JY. Combined Effect of Metastasis-Related MicroRNA, miR-34 and miR-124 Family, Methylation on Prognosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;18(1):e13\u2013e20.","DOI":"10.1016\/j.cllc.2016.06.005"},{"issue":"16","key":"582_CR31","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1158\/0008-5472.CAN-15-3367","volume":"76","author":"CS Tellez","year":"2016","unstructured":"Tellez CS, Juri DE, Do K, Picchi MA, Wang T, Liu G, et al. miR-196b is epigenetically silenced during the premalignant stage of lung carcinogenesis. Cancer Res. 2016;76(16):4741\u201351.","journal-title":"Cancer Res"},{"issue":"2","key":"582_CR32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3892\/or.2016.4882","volume":"36","author":"L Zhao","year":"2016","unstructured":"Zhao L, Feng X, Song X, Zhou H, Zhao Y, Cheng L, Jia L. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4. Oncol Rep. 2016;36(2):1007\u201315.","journal-title":"Oncol Rep"},{"issue":"11","key":"582_CR33","doi-asserted-by":"crossref","first-page":"12267","DOI":"10.18632\/oncotarget.7860","volume":"7","author":"M Tambe","year":"2016","unstructured":"Tambe M, Pruikkonen S, Maki-Jouppila J, Chen P, Elgaaen BV, Straume AH, et al. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel. Oncotarget. 2016;7(11):12267\u201385.","journal-title":"Oncotarget"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:17:12Z","timestamp":1570061832000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0582-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]},"article-number":"114"}}